Turkish Thoracic Journal
Letter to the Editor

Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations

1.

Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba

2.

Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital

3.

DNA Chip Research Inc. (Tokyo, Japan)

4.

Division of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba

Turk Thorac J 2022; 23: 364-365
DOI: 10.5152/TurkThoracJ.2022.22034
Read: 54 Downloads: 21 Published: 01 September 2022

Cite this article as: Satoh H, Miyazaki K, Sato Y, Hizawa N. Response to afatinib in a common EGFR-mutated lung adenocarcinoma with a very rare combination of compound mutations. Turk Thorac J. 2022;23(5):364-365.

Files
EISSN 2149-2530